Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Elisabetta Patorno,Ajinkya Pawar,Jessica M. Franklin,Mehdi Najafzadeh,Deborah J. Wexler,Anouk Déruaz-Luyet,Kimberly G. Brodovicz,Lily G. Bessette,Sebastian Schneeweiss

Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

2019

Elisabetta Patorno
Ajinkya Pawar
Jessica M. Franklin
Mehdi Najafzadeh
Deborah J. Wexler
Anouk Déruaz-Luyet
Kimberly G. Brodovicz
Lily G. Bessette
Sebastian Schneeweiss

The EMPA-REG OUTCOME trial showed a reduction of 35% for heart failure hospitalization (HHF) and similar incidence of myocardial infarction (MI) and Stroke in patients with Type 2 diabetes (T2D) at...

Keywords:

Medicine
Internal medicine
Interim analysis
Glucagon-like Peptide-1 Agonists
Incidence (epidemiology)
Stroke
Type 2 diabetes
Heart failure
Myocardial infarction
Empagliflozin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations